Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

BD set to add HandyLab to molecular Dx offering

This article was originally published in Clinica

  • News
  • Joseph Harvey  

Executive Summary

BD is to grow its portfolio of molecular diagnostics technology by purchasing HandyLab, a specialist in assays and automation platforms. The acquisition will follow on from an exclusive partnership between the two firms whereby BD Diagnostics aims to commercialise its molecular assays on a new platform that will integrate benchtop technology developed by Ann Arbor, Michigan-based HandyLab (www.clinica.co.uk, May 19 2009). BD said that it plans to run its GeneOhm molecular assays for methicillin-resisant Staphylococcus aureus (MRSA), Clostridium difficile and vancomycin-resistant Enterococcus (VRE) onto HandyLab’s platform and market them as the BD MAX system. Financial details of the deal, which is expected to close during the first quarter of fiscal 2010, were not disclosed.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

See All
UsernamePublicRestriction

Register

MT044583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By